STTK
Companies
NASDAQ
Shattuck Labs Inc.
Health Care
$1.05
-$0.16 (-13.22%)
Price Chart
Overview
About STTK
Shattuck Labs Inc is a clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins as an entirely new class of biologic medicine. Its product candidate, SL-172154, has been rationally designed to simultaneously inhibit the CD47/SIRPa checkpoint interaction to restore an anti-tumor immune response and to activate the CD40 costimulatory receptor to bolster an immune response. Its product candidate, SL-279252, which is being developed in collaboration with Takeda Pharmaceuticals, or Takeda, has been rationally designed to simultaneously inhibit the PD-1/PD-L1 interaction and activate the OX40 receptor.
Market Cap
$333.8M
Volume
103.2K
Avg. Volume
145.3K
P/E Ratio
-0.8878504
Dividend Yield
0.00%
Employees
82.0
Company Information
Risk & Correlation Analysis
Market Correlation
0.84
Moderate Correlation
Volatility
High (1.00)
Relative to market
Macro Factor Sensitivities
Interest Rates
High Sensitivity
Inflation
High Sensitivity
GDP Growth
High Sensitivity
Liquidity
Low Sensitivity
Commodity Prices
Low Sensitivity
Credit Quality
High Sensitivity
Portfolio Impact
Forecasts & Predictions
1-Month Target
$XXX.XX
+X.X% Potential
3-Month Target
$XXX.XX
+X.X% Potential
12-Month Target
$XXX.XX
+X.X% Potential
Technical Analysis
Based on technical indicators and chart patterns, STTK shows...
AI Sentiment Analysis
Market sentiment analysis indicates...
Key Statistics
Market Cap$333.8M
Volume103.2K
P/E Ratio-0.89
Dividend Yield0.00%
Important Dates
Next Dividend
Next Earnings
March 27, 2025Related Securities
Pricing info last updated June 19, 2025 (after market close)Other info last updated April 2, 2025